Fundraising Fox
株式会社Dioseve
Tokyo, JP · 6 employees on LinkedIn · 6 known investors
Find your way into 株式会社Dioseve
Sign up to see every warm intro you have to 株式会社Dioseve
- Paths you didn't know you had: your email and LinkedIn already hold routes to the 株式会社Dioseve team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Dioseve develops reproductive cell technology that uses a proprietary differentiation-induction method to generate oocytes and ovarian somatic cells from iPS cells. The company targets fertility and infertility challenges, aiming to help people who want to have children, particularly around age-related declines in egg and sperm function.
Also known as Dioseve · ディオシーヴ · 株式会社Dioseve
Investors · 6
How we know: Coral Capital's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: DG Daiwa Ventures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: MIRAIDOOR Co. Ltd.'s portfolio page · Not right? Tell us
How we know: Pangaea Ventures Us Inc.'s portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Company profile
researched Aug 2026株式会社Dioseve (Dioseve) is a Tokyo-based reproductive cell technology company working on infertility treatment. Its stated focus is the decline in oocyte and sperm function that accompanies aging, which reduces the likelihood of conception and birth, and it positions its germ cell technology as a way to offer options to people who want to have children.
The company's platform centers on a proprietary differentiation-induction method that derives oocytes and ovarian somatic cells from induced pluripotent stem (iPS) cells at high efficiency. Dioseve describes two development programs on its site, DIOS-001 and DIOS-101, and states an intent to apply the platform to problems that have previously lacked solutions.
Traction
Dioseve lists two pipeline programs, DIOS-001 and DIOS-101, and maintains an investors section and press coverage section on its corporate site.
▸Full profile — market position, technology, go-to-market, geography
Market position
Dioseve describes its work as applying world-leading germ cell technology to infertility, aiming to provide solutions for challenges that previously had none.
Technology
Dioseve's core technology is a proprietary differentiation-induction method that converts iPS cells into oocytes and ovarian somatic cells with high efficiency. The company frames this germ cell technology as the basis for addressing age-related declines in egg and sperm function.
Go-to-market
The company addresses infertility treatment, directing its technology at people seeking to have children, particularly those affected by age-related decline in oocyte and sperm function.
Geography
Headquarters are in Mitsui Link-Lab Shinkiba 2, Shinkiba 1-chome, Koto-ku, Tokyo. The company operates a research base in Kumamoto, located within Kumamoto University in Chuo-ku, Kumamoto City, and a US subsidiary at 214 Homer Ave, Palo Alto, California.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
▸Research sources · 1
primary sources listed
- 株式会社Diosevedioseve.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does 株式会社Dioseve do?
- Japanese biotech inducing oocytes and ovarian somatic cells from iPS cells for infertility treatment.
- Who are 株式会社Dioseve's investors?
- 株式会社Dioseve's investors include Coral Capital, DG Daiwa Ventures, MIRAIDOOR Co. Ltd., Pangaea Ventures Us Inc., Spiral Capital, StartX.
- Where is 株式会社Dioseve headquartered?
- 株式会社Dioseve is headquartered in Tokyo, JP.